Reliance Global Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Reliance Global Group, Inc. (RELI) on March 23, 2022. The filing addresses a material amendment to definitive agreements and the unregistered sale of equity securities related to a Nasdaq compliance issue.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure adjustments and regulatory compliance.
Material Changes and Events
- Nasdaq Deficiency: On January 31, 2022, the Company received a deficiency notification from Nasdaq regarding the issuance of shares in connection with a private placement (January 6, 2022) and the Medigap, Inc. asset acquisition (January 10, 2022). Nasdaq determined these issuances violated Listing Rule 5635(a).
- Remediation Plan: The Company implemented a plan accepted by Nasdaq involving the exchange of common stock for warrants.
- Share Exchanges:
- Holders exchanged 2,670,892 shares of common stock for 2,670,892 Series C Warrants and 1,222,498 Series D Warrants.
- Medigap, Inc. exchanged 606,037 shares of common stock for 606,037 Series C Warrants.
- Warrant Terms: Series C Warrants are exercisable on a one-for-one basis immediately upon shareholder approval of the financing and acquisition transactions.
- Shareholder Approval: Nine shareholders representing a majority of outstanding shares signed a written consent on March 18, 2022. This consent becomes effective 20 calendar days after the filing of a Definitive Schedule 14C (with a Preliminary Schedule 14C due by April 1, 2022).
Outlook, Risks, and Contingencies
The primary contingency identified is the effectiveness of the shareholder consent, which is required to finalize the warrant exchange and resolve the Nasdaq listing deficiency. The filing does not contain forward-looking guidance on financial performance or management commentary on future operations.
Investor Verification Checklist
- Verify the filing date and status of the Preliminary and Definitive Schedule 14C to confirm the timeline for shareholder consent effectiveness.
- Confirm the final terms of the Series C and Series D Warrants, including expiration dates and exercise prices, which are not detailed in this summary.
- Monitor Nasdaq communications to ensure the listing deficiency has been fully resolved following the remediation plan.
- Review the impact of the share exchanges on the total outstanding share count and potential future dilution upon warrant exercise.